DK1539956T3 - GEF-H1b: Biomarkere, komplekser, analyser og terapeutiske anvendelser deraf - Google Patents

GEF-H1b: Biomarkere, komplekser, analyser og terapeutiske anvendelser deraf

Info

Publication number
DK1539956T3
DK1539956T3 DK03763085.2T DK03763085T DK1539956T3 DK 1539956 T3 DK1539956 T3 DK 1539956T3 DK 03763085 T DK03763085 T DK 03763085T DK 1539956 T3 DK1539956 T3 DK 1539956T3
Authority
DK
Denmark
Prior art keywords
gef
biomarkers
assays
complexes
therapeutic uses
Prior art date
Application number
DK03763085.2T
Other languages
English (en)
Inventor
Marinella G Callow
Sergey Zozulya
Mikhail L Gishizky
Tod R Smeal
Bahija Jallal
Original Assignee
Sugen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sugen Inc filed Critical Sugen Inc
Application granted granted Critical
Publication of DK1539956T3 publication Critical patent/DK1539956T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DK03763085.2T 2002-07-05 2003-07-02 GEF-H1b: Biomarkere, komplekser, analyser og terapeutiske anvendelser deraf DK1539956T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US39360002P 2002-07-05 2002-07-05
US46005303P 2003-04-04 2003-04-04
PCT/US2003/020743 WO2004005529A2 (en) 2002-07-05 2003-07-02 GEF-H1b: BIOMARKERS, COMPLEXES, ASSAYS AND THERAPEUTIC USES THEREOF

Publications (1)

Publication Number Publication Date
DK1539956T3 true DK1539956T3 (da) 2011-03-28

Family

ID=30118381

Family Applications (1)

Application Number Title Priority Date Filing Date
DK03763085.2T DK1539956T3 (da) 2002-07-05 2003-07-02 GEF-H1b: Biomarkere, komplekser, analyser og terapeutiske anvendelser deraf

Country Status (9)

Country Link
US (3) US7439329B2 (da)
EP (1) EP1539956B1 (da)
JP (1) JP4522855B2 (da)
AT (1) ATE497002T1 (da)
AU (1) AU2003256356A1 (da)
DE (1) DE60335883D1 (da)
DK (1) DK1539956T3 (da)
PT (1) PT1539956E (da)
WO (1) WO2004005529A2 (da)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6861442B1 (en) * 1998-12-30 2005-03-01 Sugen, Inc. PYK2 and inflammation
US20100247552A1 (en) 2006-11-10 2010-09-30 Massachusetts Institute Of Technology Pak modulators

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4939224A (en) * 1987-02-26 1990-07-03 The Salk Institute Biotechnology/Industrial Associates, Inc. Vasoactive intestinal peptide analogs
DE4412174A1 (de) * 1994-04-08 1995-10-19 Schramm Wolfgang Prof Dr Peptide, Verfahren zu ihrer Herstellung und ihre Verwendung
US5863532A (en) * 1996-03-14 1999-01-26 The Regents Of The University Of California Compositions and methods comprising cytostatic protein kinase
DE69926742T2 (de) * 1998-04-14 2006-06-14 Sugen Inc Ste20-verwandte proteinkinasen
US6013500A (en) * 1998-05-21 2000-01-11 The Trustees Of Columbia University In The City Of New York PAK4, a novel gene encoding a serine/threonine kinase
CA2387754A1 (en) * 1999-10-29 2001-05-10 Human Genome Sciences, Inc. 10 human secreted proteins
WO2003068940A2 (en) * 2002-02-14 2003-08-21 Curagen Corporation Complexes and methods of using same

Also Published As

Publication number Publication date
US20110159532A1 (en) 2011-06-30
US7439329B2 (en) 2008-10-21
WO2004005529A3 (en) 2004-07-22
ATE497002T1 (de) 2011-02-15
AU2003256356A8 (en) 2004-01-23
EP1539956B1 (en) 2011-01-26
JP4522855B2 (ja) 2010-08-11
EP1539956A2 (en) 2005-06-15
US20040091907A1 (en) 2004-05-13
JP2005532062A (ja) 2005-10-27
PT1539956E (pt) 2011-03-16
EP1539956A4 (en) 2006-09-06
DE60335883D1 (de) 2011-03-10
AU2003256356A1 (en) 2004-01-23
US7871786B2 (en) 2011-01-18
US20090130695A1 (en) 2009-05-21
WO2004005529A2 (en) 2004-01-15

Similar Documents

Publication Publication Date Title
GB2451042A (en) Reagents and methods for using human embryonic stem cells to evaluate toxicity of pharmaceutical compounds and other chemicals
DE602006008310D1 (de) Biomarker für eierstockkrebs: mit ctap3 verwandte proteine
Yang et al. Efficient targeted oncogenic KRASG12C degradation via first reversible-covalent PROTAC
Nielsen-Marsh et al. Osteocalcin protein sequences of Neanderthals and modern primates
ATE501267T1 (de) Apolipoprotein-a-ii-isoform als biomarker für prostatakrebs
BRPI0607306A2 (pt) derivados de quinoxalina como agentes anti-tumor
Kopra et al. Homogeneous dual-parametric-coupled assay for simultaneous nucleotide exchange and KRAS/RAF-RBD interaction monitoring
Schulz-Fincke et al. Structure-activity studies on N-Substituted tranylcypromine derivatives lead to selective inhibitors of lysine specific demethylase 1 (LSD1) and potent inducers of leukemic cell differentiation
WO2004076679A3 (en) Serum macrophage migration inhibitory factor (mif) as marker for prostate cancer
WO2007002069A3 (en) Serum biomarkers for breast cancer
DE602005014386D1 (de) Verwendung von cyfra 21-1 und osteopontin als marker für kolorektalkarzinome
TR201900481T4 (tr) Bağışıklık testi için aparat ve kit.
WO2008048508A3 (en) Prognostic biomarkers in patients with ovarian cancer
WO2005085863A3 (en) Biomarker: compound correlations in cancer diagnosis and therapy
Miao et al. A high-throughput targeted proteomic approach for comprehensive profiling of methylglyoxal-induced perturbations of the human kinome
MXPA05006382A (es) Uso de nicotinamida n-metiltransferasa como un marcador para cancer colorrectal.
WO2005103713A3 (en) Methods, compositions and compound assays for inhibiting amyloid-beta protein production
WO2002102229A3 (en) Diagnosing tumorigenicity and determining resistance to anticancer therapy
Hegedus et al. Proteomic analysis of childhood leukemia
ATE433115T1 (de) Timp-2 als ziel/marker des versagens von beta- zellen
Tello et al. A “fluorescence switch” technique increases the sensitivity of proteomic detection and identification of S‐nitrosylated proteins
Tay et al. MethylQuant: A tool for sensitive validation of enzyme-mediated protein methylation sites from heavy-methyl SILAC data
DE602007006671D1 (de) Verwendung von nnmt als marker für lungenkrebs
DE602005013430D1 (de) Verwendung von asc als marker für kolorektalkarzinome
DK1539956T3 (da) GEF-H1b: Biomarkere, komplekser, analyser og terapeutiske anvendelser deraf